Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2025-01-03 00:00:00 ET · period of report 2025-01-02 · accession 0001415889-25-000675 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-03 | 2025-01-02 | JANX | Campbell David Alan | Pres, CEO, Dir | A - Grant | $0.00 | +81.0K | 298.1K | +37% | $0 |
| D | 2025-01-03 | 2025-01-02 | JANX | Campbell David Alan | Pres, CEO, Dir | A - Grant | $0.00 | +283.5K | 283.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | A | A | 81,000 | $0.00 | 298,054 | D | — | — | (F1) Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. |
| 2 | Derivative | Stock option (right to buy) | 2025-01-02 | A | A | 283,500 | $0.00 | 283,500 | D | $53.24 · — to 2035-01-01 | 283,500 Common Stock | (F2) 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. |